Intravenous contrast-enhanced CT can be used for CT-based attenuation correction in clinical 111In-octreotide SPECT/CT

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Intravenous contrast-enhanced CT can be used for CT-based attenuation correction in clinical 111In-octreotide SPECT/CT. / Klausen, Thomas Levin; Mortensen, Jann; de Nijs, Robin; Andersen, Flemming Littrup; Højgaard, Liselotte; Beyer, Thomas; Holm, Søren.

In: EJNMMI Physics, Vol. 2, 3, 12.02.2015, p. 1-13.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Klausen, TL, Mortensen, J, de Nijs, R, Andersen, FL, Højgaard, L, Beyer, T & Holm, S 2015, 'Intravenous contrast-enhanced CT can be used for CT-based attenuation correction in clinical 111In-octreotide SPECT/CT', EJNMMI Physics, vol. 2, 3, pp. 1-13. https://doi.org/10.1186/s40658-015-0108-1

APA

Klausen, T. L., Mortensen, J., de Nijs, R., Andersen, F. L., Højgaard, L., Beyer, T., & Holm, S. (2015). Intravenous contrast-enhanced CT can be used for CT-based attenuation correction in clinical 111In-octreotide SPECT/CT. EJNMMI Physics, 2, 1-13. [3]. https://doi.org/10.1186/s40658-015-0108-1

Vancouver

Klausen TL, Mortensen J, de Nijs R, Andersen FL, Højgaard L, Beyer T et al. Intravenous contrast-enhanced CT can be used for CT-based attenuation correction in clinical 111In-octreotide SPECT/CT. EJNMMI Physics. 2015 Feb 12;2:1-13. 3. https://doi.org/10.1186/s40658-015-0108-1

Author

Klausen, Thomas Levin ; Mortensen, Jann ; de Nijs, Robin ; Andersen, Flemming Littrup ; Højgaard, Liselotte ; Beyer, Thomas ; Holm, Søren. / Intravenous contrast-enhanced CT can be used for CT-based attenuation correction in clinical 111In-octreotide SPECT/CT. In: EJNMMI Physics. 2015 ; Vol. 2. pp. 1-13.

Bibtex

@article{a783533038b641c0ba0c4be0bd18220c,
title = "Intravenous contrast-enhanced CT can be used for CT-based attenuation correction in clinical 111In-octreotide SPECT/CT",
abstract = "BACKGROUND: CT-based attenuation correction (CT-AC) using contrast-enhancement CT impacts (111)In-SPECT image quality and quantification. In this study we assessed and evaluated the effect.METHODS: A phantom (5.15 L) was filled with an aqueous solution of In-111. Three SPECT/CT scans were performed: (A) no IV contrast, (B) with 100-mL IV contrast, and (C) with 200-mL IV contrast added. Scan protocol included a localization CT, a low-dose CT (LD), and a full-dose CT (FD). Phantom, LD and FD scan series were performed at 90, 120, and 140 kVp. Phantom data were evaluated looking at mean counts in a central volume. Ten patients referred for (111)In-octreotide scintigraphy were scanned according to our clinical (111)In-SPECT/CT protocol including a topogram, a LD (140 kVp), and a FD (120 kVp). The FD/contrast-enhanced CT was acquired in both arterial (FDAP) and venous phase (FDVP) following a mono-phasic IV injection of 125-mL Optiray (4.5 mL/s). For patient data, we report image quality, Krenning scores, and mean/max values for liver and tumor regions.RESULTS: Phantoms: in uncorrected emission data, mean counts (average ± SD) decreased with increasing IV concentration: (A) 119 ± 9, (B) 113 ± 8, and (C) 110 ± 9. For all attenuation correction (AC) scans, the mean values increased with increasing iodine concentration.PATIENTS: there were no visible artifacts in single photon emission computed tomography (SPECT) following CT-AC with contrast-enhanced CT. The average score of image quality was 4.1 ± 0.3, 3.8 ± 0.4, and 4.2 ± 0.4 for LD, arterial phase, and venous phase, respectively. A total of 16 lesions were detected. The Krenning scores of 13/16 lesions were identical across all scan series. The max pixel values for the 16 lesions showed generally lower values for LD than for contrast-enhanced CT.CONCLUSIONS: In (111)In-SPECT/CT imaging of phantoms and patients, the use of IV CT contrast did neither degrade the SPECT image quality nor affect the clinical Krenning score. Reconstructed counts in healthy liver tissues were unaffected, and there was a generally lower count value in lesions following CT-AC based on the LD non-enhanced images. Overall, for clinical interpretation, no separate low-dose CT is required for CT-AC in (111)In-SPECT/CT.",
author = "Klausen, {Thomas Levin} and Jann Mortensen and {de Nijs}, Robin and Andersen, {Flemming Littrup} and Liselotte H{\o}jgaard and Thomas Beyer and S{\o}ren Holm",
year = "2015",
month = "2",
day = "12",
doi = "10.1186/s40658-015-0108-1",
language = "English",
volume = "2",
pages = "1--13",
journal = "E J N M M I Physics",
issn = "2197-7364",
publisher = "SpringerOpen",

}

RIS

TY - JOUR

T1 - Intravenous contrast-enhanced CT can be used for CT-based attenuation correction in clinical 111In-octreotide SPECT/CT

AU - Klausen, Thomas Levin

AU - Mortensen, Jann

AU - de Nijs, Robin

AU - Andersen, Flemming Littrup

AU - Højgaard, Liselotte

AU - Beyer, Thomas

AU - Holm, Søren

PY - 2015/2/12

Y1 - 2015/2/12

N2 - BACKGROUND: CT-based attenuation correction (CT-AC) using contrast-enhancement CT impacts (111)In-SPECT image quality and quantification. In this study we assessed and evaluated the effect.METHODS: A phantom (5.15 L) was filled with an aqueous solution of In-111. Three SPECT/CT scans were performed: (A) no IV contrast, (B) with 100-mL IV contrast, and (C) with 200-mL IV contrast added. Scan protocol included a localization CT, a low-dose CT (LD), and a full-dose CT (FD). Phantom, LD and FD scan series were performed at 90, 120, and 140 kVp. Phantom data were evaluated looking at mean counts in a central volume. Ten patients referred for (111)In-octreotide scintigraphy were scanned according to our clinical (111)In-SPECT/CT protocol including a topogram, a LD (140 kVp), and a FD (120 kVp). The FD/contrast-enhanced CT was acquired in both arterial (FDAP) and venous phase (FDVP) following a mono-phasic IV injection of 125-mL Optiray (4.5 mL/s). For patient data, we report image quality, Krenning scores, and mean/max values for liver and tumor regions.RESULTS: Phantoms: in uncorrected emission data, mean counts (average ± SD) decreased with increasing IV concentration: (A) 119 ± 9, (B) 113 ± 8, and (C) 110 ± 9. For all attenuation correction (AC) scans, the mean values increased with increasing iodine concentration.PATIENTS: there were no visible artifacts in single photon emission computed tomography (SPECT) following CT-AC with contrast-enhanced CT. The average score of image quality was 4.1 ± 0.3, 3.8 ± 0.4, and 4.2 ± 0.4 for LD, arterial phase, and venous phase, respectively. A total of 16 lesions were detected. The Krenning scores of 13/16 lesions were identical across all scan series. The max pixel values for the 16 lesions showed generally lower values for LD than for contrast-enhanced CT.CONCLUSIONS: In (111)In-SPECT/CT imaging of phantoms and patients, the use of IV CT contrast did neither degrade the SPECT image quality nor affect the clinical Krenning score. Reconstructed counts in healthy liver tissues were unaffected, and there was a generally lower count value in lesions following CT-AC based on the LD non-enhanced images. Overall, for clinical interpretation, no separate low-dose CT is required for CT-AC in (111)In-SPECT/CT.

AB - BACKGROUND: CT-based attenuation correction (CT-AC) using contrast-enhancement CT impacts (111)In-SPECT image quality and quantification. In this study we assessed and evaluated the effect.METHODS: A phantom (5.15 L) was filled with an aqueous solution of In-111. Three SPECT/CT scans were performed: (A) no IV contrast, (B) with 100-mL IV contrast, and (C) with 200-mL IV contrast added. Scan protocol included a localization CT, a low-dose CT (LD), and a full-dose CT (FD). Phantom, LD and FD scan series were performed at 90, 120, and 140 kVp. Phantom data were evaluated looking at mean counts in a central volume. Ten patients referred for (111)In-octreotide scintigraphy were scanned according to our clinical (111)In-SPECT/CT protocol including a topogram, a LD (140 kVp), and a FD (120 kVp). The FD/contrast-enhanced CT was acquired in both arterial (FDAP) and venous phase (FDVP) following a mono-phasic IV injection of 125-mL Optiray (4.5 mL/s). For patient data, we report image quality, Krenning scores, and mean/max values for liver and tumor regions.RESULTS: Phantoms: in uncorrected emission data, mean counts (average ± SD) decreased with increasing IV concentration: (A) 119 ± 9, (B) 113 ± 8, and (C) 110 ± 9. For all attenuation correction (AC) scans, the mean values increased with increasing iodine concentration.PATIENTS: there were no visible artifacts in single photon emission computed tomography (SPECT) following CT-AC with contrast-enhanced CT. The average score of image quality was 4.1 ± 0.3, 3.8 ± 0.4, and 4.2 ± 0.4 for LD, arterial phase, and venous phase, respectively. A total of 16 lesions were detected. The Krenning scores of 13/16 lesions were identical across all scan series. The max pixel values for the 16 lesions showed generally lower values for LD than for contrast-enhanced CT.CONCLUSIONS: In (111)In-SPECT/CT imaging of phantoms and patients, the use of IV CT contrast did neither degrade the SPECT image quality nor affect the clinical Krenning score. Reconstructed counts in healthy liver tissues were unaffected, and there was a generally lower count value in lesions following CT-AC based on the LD non-enhanced images. Overall, for clinical interpretation, no separate low-dose CT is required for CT-AC in (111)In-SPECT/CT.

U2 - 10.1186/s40658-015-0108-1

DO - 10.1186/s40658-015-0108-1

M3 - Journal article

C2 - 26501805

VL - 2

SP - 1

EP - 13

JO - E J N M M I Physics

JF - E J N M M I Physics

SN - 2197-7364

M1 - 3

ER -

ID: 162711275